PVLA — Palvella Therapeutics Share Price
0.000.00%
Last trade - 00:00- $270.11m
- $186.51m
- 39
- 26
- 70
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.31 | ||
| Price to Tang. Book | 4.31 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.5% | ||
| Return on Equity | -39.02% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 29.32 | 31.42 | 25.9 | 42.81 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Directors
- James Geraghty NEC (67)
- Stephen Yoder PRE (45)
- Thomas Bures CFO (47)
- Hitto Kaufmann SVP (50)
- Ahmed Mousa SVP (37)
- Tim Demuth SVP
- Shane Olwill SVP
- Ann Barbier IND (57)
- Peter Kiener IND (69)
- Christopher Kiritsy IND (56)
- Michael Richman IND (60)
- Maya Said IND (44)
- Matthew Sherman IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 24th, 2013
- Public Since
- December 18th, 2014
- No. of Shareholders
- 103
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 11,042,965
- Address
- 125 Strafford Ave, Suite 360, WAYNE, 19087
- Web
- https://palvellatx.com/
- Phone
- +1 4842531461
- Auditors
- Ernst & Young LLP
Upcoming Events for PVLA
Q2 2025 Pieris Pharmaceuticals Inc Earnings Release
Similar to PVLA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Palvella Therapeutics share price?
As of Today at 22:33 UTC, shares in Palvella Therapeutics are trading at $24.46. This share price information is delayed by 15 minutes.
How has the Palvella Therapeutics share price performed this year?
Shares in Palvella Therapeutics last closed at $24.46 and the price had moved by +117.62% over the past 365 days. In terms of relative price strength the Palvella Therapeutics share price has outperformed the S&P500 Index by +96.23% over the past year.
What are the analyst and broker recommendations for Palvella Therapeutics?
The overall consensus recommendation for Palvella Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Palvella Therapeutics dividend yield?
Palvella Therapeutics does not currently pay a dividend.
Does Palvella Therapeutics pay a dividend?
Palvella Therapeutics does not currently pay a dividend.
When does Palvella Therapeutics next pay dividends?
Palvella Therapeutics does not currently pay a dividend.
How do I buy Palvella Therapeutics shares?
To buy shares in Palvella Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Palvella Therapeutics?
As of the previous close price of $24.46, shares in Palvella Therapeutics had a market capitalisation of $270.11m.
Where are Palvella Therapeutics shares listed?
Here are the trading details for Palvella Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PVLA
What kind of share is Palvella Therapeutics?
Based on an overall assessment of its quality, value and momentum Palvella Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Palvella Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Palvella Therapeutics is $49.33. That is 101.68% above the last closing price of $24.46.
Analysts covering Palvella Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$5.49 for the next financial year.
Find out moreWhat is the trend in the Palvella Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Palvella Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +42.03%.
As of the last closing price of $24.46, shares in Palvella Therapeutics were trading +37.35% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Palvella Therapeutics PE Ratio?
The Palvella Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $24.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Palvella Therapeutics?
Palvella Therapeutics' management team is headed by:
- James Geraghty - NEC
- Stephen Yoder - PRE
- Thomas Bures - CFO
- Hitto Kaufmann - SVP
- Ahmed Mousa - SVP
- Tim Demuth - SVP
- Shane Olwill - SVP
- Ann Barbier - IND
- Peter Kiener - IND
- Christopher Kiritsy - IND
- Michael Richman - IND
- Maya Said - IND
- Matthew Sherman - IND